Because he seeks out new experiences, Novoeight® has portability to keep him on the go

He needs to trust that he can go where life leads him

Whether your patient is planning a trip or looking for storage solutions at home, Novoeight® gives patients storage flexibility.1,a

Boy, who lives with hemophilia A, near the lake with his friends.


Malcolm, 18 years old, lives with hemophilia A.


 



 

80% of patients and HCP prefer FVIII treatment storage flexibility

80% of patients and caregivers surveyed prefer a FVIII treatment that can be stored at a higher temperature for longer durations.5,b


 



 

Novoeight® has room temperature stability to keep up with his active lifestyle

Novoeight storage parameters - Up to 86 degrees for 12 month and longest room temperature storage time.


Please see Prescribing Information for complete storage instructions.

 


 



 

Novoeight vials with one-size syringe

Quick reconstitution with MixPro®c

  • Each vial comes with MixPro®, a one-size syringe pre-filled with 4 mL of diluent for quick reconstitution1
  • Multiple dose strengths help more patients infuse with fewer vials1
  • The peel-and-stick label may help your patient track his doses
    • The adhesive on the peel-off vial label is made with natural rubber latex


 



 

See for yourself

Watch a dose of Novoeight® being reconstituted, and see how quick it is to attach, twist, and mix. Please see the full Prescribing Information for complete Instructions for Use. 

Novoeight vials with one-size syringe


 



 

Novoeight patient conversation guide

Supporting the conversation

Get useful tools and information that can help you talk with your patient about Novoeight®, and discuss all the ways it may fit into his world. 

Novoeight Travel Kit

Makes traveling easy

Your patient on Novoeight® can order a free Travel Kit through a Novo Nordisk Representative. If he needs help finding a Rep, he can call 1-844-NOVOSEC (1-844-668-6732).


a
Compared with other recombinant FVIII products.2-4
b
From a Web-based survey of 145 individuals.
cCompared with vial-to-vial reconstitution.

References: 1. Novoeight® [package insert]. Plainsboro, NJ: Novo Nordisk Inc.; 2014. 2. Advate® [package insert]. Westlake Village, CA: Baxter Healthcare Corporation; 2014. 3. Eloctate™ [package insert]. Cambridge, MA: Biogen Idec Inc.; 2014. 4. Kogenate® FS [package insert]. Tarrytown, NY: Bayer HealthCare LLC; 2014. 5. DiBenedetti DB, Coles TM, Sharma T, Pericleous L, Kulkarni R. Assessing patients’ and caregivers’ perspectives on stability of factor VIII products for haemophilia A: a web-based study in the United States and Canada. Haemophilia. 2014;20(4):e296-e303.


 



 

Selected Important Safety Information

Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins.

Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment.

Indications and Usage

Novoeight® (Antihemophilic Factor [Recombinant]) is indicated for use in adults and children with hemophilia A for control and prevention of bleeding, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes.

Novoeight® is not indicated for the treatment of von Willebrand disease.
 

Important Safety Information

Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins.

Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment.

Development of activity-neutralizing antibodies (inhibitors) may occur.  If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an appropriate dose, perform an assay that measures factor VIII inhibitor concentration.

The most frequently reported adverse reactions (≥0.5%) were injection site reactions, increased hepatic enzymes, and pyrexia.


Please click here for Novoeight® Prescribing Information.